[PDF] Top 20 Diseño de una infraestructura de Televisión Digital Terrestre con el estándar ISDB-Tb.
Has 10000 "Diseño de una infraestructura de Televisión Digital Terrestre con el estándar ISDB-Tb." found on our website. Below are the top 20 most common "Diseño de una infraestructura de Televisión Digital Terrestre con el estándar ISDB-Tb.".
Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
... Although we followed best practices in budget impact modeling and carefully selected the data to include, results should be considered in light of the limitations. Due to a lack of published data on ... See full document
11
Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors
... radiolabeled somatostatin analogues in tumor tissues ...the impact of peptide mass on the uptake of 68 Ga-DOTATOC in NET revealed a saturable tracer accumulation in nor- mal organs (spleen and liver) after ... See full document
14
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
... Abstract: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and hetero- geneous class of ...of treatment, non-surgical therapies play a role in the setting of unresectable and ... See full document
107
Original Article Safety and tolerability of sequencing somatostatin analogs (octreotide to lanreotide depot) in the treatment of neuroendocrine tumors: an institutional case series
... In NeuroEndocrine Tumors (CLARINET), established lanreotide depot as the first Food and Drug Administration-approved synthetic somatosta- tin analog (SSA) for treatment of patients with well or ... See full document
81
A clinical and radiological objective tumor response with somatostatin analogs (SSA) in well-differentiated neuroendocrine metastatic tumor of the ileum: a case report
... The treatment may be considered in therapy-naïve, metastatic patients without a prior observation period of spontaneous tumor ...if treatment is started early after the initial diagnosis, as compared ... See full document
15
Optimized production and quality control of 68Ga-DOTATATE
... Introduction: Optimized production and quality control of 68 Ga-DOTATATE as an efficient and preferable PET radiotracer for somatostatin receptor imaging in neuroendocrine tumors is o[r] ... See full document
25
Multimodal Somatostatin Receptor Theranostics Using [64Cu]Cu-/[177Lu]Lu-DOTA-(Tyr3)octreotate and AN-238 in a Mouse Pheochromocytoma Model
... targeting efficiency to octreotide and AN-238. Apparently, these differences reflect the order of mSSTR2 binding affinities of the compounds as well as their plasma half-lives [44-46]. In the in vivo targeting ... See full document
34
A ten year retrospective analysis of gastroenteropancreatic neuroendocrine tumors (GEP NETs) in Malaysia
... The management of GEP-NETs should involve multiple disciplines throughout the course of the disease from diagnosis to addressing its complications, thus ensuring appropriate and accurate investigations, functional ... See full document
178
Developmental trends in targeted radionuclide therapy of neuroendocrine tumors
... Survival and response after peptide receptor radionuclide therapy with [ 90 Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl[r] ... See full document
65
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
... Generally, patients included in experimental protocols have a positive NET histology and a positive SSTR scintig- raphy with 111In OctreoScan or 68Ga PET-Dota-peptide. A scan is considered positive if lesion uptake is ... See full document
16
Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)
... cinoid tumors has been reported in various studies to be somewhere between 80% and ...of somatostatin receptors, which may have bearing on the efficacy of treatment with somatostatin ... See full document
10
A case of malignant insulinoma responsive to somatostatin analogs treatment
... Background: Insulinoma is a rare tumour representing 1 – 2% of all pancreatic neoplasms and it is malignant in only 10% of cases. Locoregional invasion or metastases define malignancy, whereas the dimension (> 2 cm), ... See full document
23
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
... and treatment) while receiving maximum approved doses of the currently available SSA for 3 months prior to study entry; Karnofsky performance status $60; and adequate bone marrow, renal, and hepatic ... See full document
5
Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours – an analysis based on the CLARINET study
... the impact of time to death on HRQL is important to consider, especially in the weeks preceding death [19], and clinical experts sug- gest that utility for GEP-NET patients may ... See full document
70
The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 18F-labeled Somatostatin Analog Development
... SSTRs belong to the G-protein-coupled receptor family and are frequently upregulated in grade 1–2, well-differentiated NETs. Out of the five subtypes that have been evaluated (SSTR1-SSTR5), SSTR2 is predominantly ... See full document
6
Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis
... “hematologic” or “hematological”) and (“neuroendocrine tumor” or “neuroendocrine tumour” or “neuroendocrine neoplasm” or “neoplasm cancer” or “neoplasm malignancy” or “carcinoid” or “insulinoma” or ... See full document
15
The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
... expanded upon that recommendation as they retrospectively evaluated a total of 15 patients who had received a median of 9 cycles (range, 8-13 cycles) with a median cumulative administered activity of 63.8 GBq (range, ... See full document
6
Original Article Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors
... All 40 tumor samples, originating both from pri- mary tumors and metastases from 21 patients with GEP-NET were analyzed retrospectively for SSTR1 to 5 (Figure 1). The samples were con- ventionally fixed in ... See full document
165
Clinical utility of lanreotide Autogel<sup>®</sup> in gastroenteropancreatic neuroendocrine tumors
... VIP-secreting tumors which cause the Verner–Morrison syndrome, charac- terized by watery diarrhea, hypokalemia, achlorhydria, weight loss, metabolic acidosis, hypercalcemia, glucose intolerance, and ... See full document
20
Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
... the treatment with long acting preparations of SST analogues consists in an intramus- cular injection ...the treatment, by increasing the analogue dosage (for octreotide with gradual increments of 10 mg ... See full document
8
Related subjects